Revolution Medicines, Inc.
RVMD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 17 sales; 693 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesRVMDW
13F holders, Q2 2024
Institutional positions in Revolution Medicines, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 223
- +15 vs. Q1 2024
- Shares held
- 168.4M
- +7.92M (+4.9%) vs. Q1 2024
- Total value
- $6.54B
- +$1.36B (+26.4%) vs. Q1 2024
- New holders
- 40
- 84 more added
- Sold out
- 25
- 59 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RVMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 693 | $40.1B |
| Q1 2026 | 514 | $19.1B |
| Q4 2025 | 387 | $15.9B |
| Q3 2025 | 323 | $8.96B |
| Q2 2025 | 308 | $7.02B |
| Q1 2025 | 284 | $6.83B |
| Q4 2024 | 281 | $8.45B |
| Q3 2024 | 255 | $7.74B |
| Q2 2024 | 223 | $6.54B |
| Q1 2024 | 210 | $5.18B |
| Q4 2023 | 184 | $4.59B |
| Q3 2023 | 168 | $3.11B |
| Q2 2023 | 139 | $2.99B |
| Q1 2023 | 152 | $2.34B |
| Q4 2022 | 135 | $2.10B |
| Q3 2022 | 142 | $1.74B |
| Q2 2022 | 135 | $1.49B |
| Q1 2022 | 126 | $1.89B |
| Q4 2021 | 117 | $1.85B |
| Q3 2021 | 114 | $1.99B |
| Q2 2021 | 130 | $2.23B |
| Q1 2021 | 128 | $3.05B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Revolution Medicines, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Holocene Advisors, LP | 2,203,474 | $85.5M | 0.36% | −218,937−9.0% | Reduced |
| Balyasny Asset Management LLC | 2,363,584 | $91.7M | 0.24% | +708,689+42.8% | Added |
| AH Capital Management, L.L.C. | 2,748,523 | $106.7M | 9.10% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 3,090,073 | $119.9M | 2.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 3,115,575 | $120.9M | 0.01% | −393,529−11.2% | Reduced |
| Woodline Partners LP | 3,290,791 | $127.7M | 1.22% | −506,357−13.3% | Reduced |
| Geode Capital Management, LLC | 3,335,656 | $129.5M | 0.01% | +282,965+9.3% | Added |
| Boxer Capital, LLC | 4,279,464 | $166.1M | 8.75% | 00.0% | Unchanged |
| Casdin Capital, LLC | 4,406,875 | $171.0M | 13.06% | −1,210,724−21.6% | Reduced |
| Janus Henderson Group PLC | 4,640,218 | $180.1M | 0.10% | +728,099+18.6% | Added |
| Bellevue Group AG | 5,029,100 | $195.2M | 3.17% | −44,500−0.9% | Reduced |
| State Street Corp | 5,071,068 | $196.8M | 0.01% | −314,952−5.8% | Reduced |
| Price T Rowe Associates Inc | 5,216,659 | $202.5M | 0.02% | +402,349+8.4% | Added |
| Paradigm Biocapital Advisors LP | 5,259,089 | $204.1M | 7.81% | +2,344,114+80.4% | Added |
| Alphabet Inc. | 5,307,075 | $206.0M | 10.43% | +5,563+0.1% | Added |
| FMR LLC | 5,625,856 | $218.3M | 0.01% | +1,459,091+35.0% | Added |
| BVF Inc | 5,981,212 | $232.1M | 6.51% | 00.0% | Unchanged |
| Nextech Invest AG | 6,296,740 | $244.4M | 41.11% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 7,569,090 | $293.8M | 3.75% | +19,841+0.3% | Added |
| Farallon Capital Management, L.L.C. | 9,757,692 | $378.7M | 2.23% | +2,249,820+30.0% | Added |
| BlackRock Inc. | 13,408,713 | $520.4M | 0.01% | +1,100,711+8.9% | Added |
| Wellington Management Group LLP | 13,660,196 | $530.2M | 0.09% | −1,054,530−7.2% | Reduced |
| Vanguard Group Inc | 14,378,297 | $558.0M | 0.01% | −378,815−2.6% | Reduced |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −618,885−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −116,156−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −68,744−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −64,053−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −44,938−100.0% | Sold out |
| Blackstone Group Inc. | 0 | $0 | 0.00% | −37,197−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −30,422−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −27,904−100.0% | Sold out |
| Duality Advisers, LP | 0 | $0 | 0.00% | −25,623−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −14,000−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −13,889−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −11,545−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −10,500−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −9,200−100.0% | Sold out |
| Mackenzie Financial Corp | 0 | $0 | 0.00% | −8,932−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −8,400−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −8,320−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −7,856−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −7,661−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −7,328−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −3,335−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −1,513−100.0% | Sold out |
| Armstrong Advisory Group, Inc | 0 | $0 | 0.00% | −304−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |
| Shell Asset Management Co | – | – | – | – | Not filed |